DEGRADER-ANTIBODY CONJUGATES
Precision degradation for hard-to-reach cancer targets
3C Therapeutics is building a new class of precision cancer therapeutics. Our TriCore platform pairs antibody-based delivery with targeted protein degradation to reach and destroy disease-driving proteins inside tumor cells, with an initial focus on aggressive solid tumors.
Our platform
Degrader-antibody conjugates
DACs combine the precision of monoclonal antibodies with the potent catalytic power of protein degraders.
Expanded target reach
TriCore is purpose-built to address targets that conventional ADCs and small-molecule degraders can’t reach.
Antibody-directed precision
Antibodies carry degrader payloads to tumor cells, with the goal of widening the therapeutic window relative to systemic degraders.
Built for speed
A modular platform designed for rapid development of DAC candidates across a broad range of cancer targets.
our leadership
Leadership with a track record from discovery to approval and exit
Meet the full team →
Daniel Wattier
Co-Founder & CEO
Dan is a seasoned biotech executive with over two decades of experience in drug development, company formation, and global commercialization. He was the founding CEO of Valocor Therapeutics, the predecessor company to Dermira (NASDAQ: DERM), which Eli Lilly acquired for $1.1B. He also served as CEO of ImStar Therapeutics, an early-stage biotech company developing novel therapeutics for ALS. Earlier in his career, Dan led early commercialization efforts for Remicade® at Centocor (now part of Johnson & Johnson), a cornerstone in the development of J&J’s top-selling pharmaceutical product. He later held senior corporate development roles at QLT Inc., advancing global partnerships with Novartis, Astellas, and Sanofi. As CEO of 3C Therapeutics, Dan brings deep expertise in company building, venture financing, and strategic partnering to drive the advancement of the company’s novel DAC (Degrader-Antibody Conjugate) platform. He is also a Strategic Commercialization Advisor to Genome BC and has served on national and industry advisory boards supporting biotech innovation across Canada.
Tony Polverino
CSO & Scientific Advisor
Tony has been a leader in the biotechnology and pharmaceutical sector for more than 30 years. He currently serves on the Board of Directors for Brainstorm Cell Therapeutics, a company developing innovative therapies for the treatment of neurodegenerative diseases. He was formerly the Executive Vice President, Early Development and Chief Scientific Officer at Zymeworks Inc., where he oversaw the development of Zanidatamab, eventually out-licensed to Jazz Pharmaceuticals in a multi-billion-dollar deal. Prior to Zymeworks, Tony served as interim Chief Scientific Officer at Kite, which Gilead acquired for $11.9B. During his tenure, Kite developed axicabtagene ciloleucel (Yescarta®), a chimeric antigen receptor (CAR-T) cell immunotherapy approved in the United States for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. Before joining Kite, Tony spent 20 years at Amgen, holding various positions of increasing responsibility, including Director in the Oncology Department and Executive Director and Head of the Therapeutic Innovation Unit, where he led the discovery and development of multiple IND programs. Tony earned his PhD from Flinders University and a BSc from Adelaide University.
David Wood
Chief Financial Officer
David has over 30 years of experience in management of both early and late stage companies in North America and the U.K. and has over 25 years of experience in the biopharmaceutical industry, where he has overseen several M&A transactions and numerous financings. He previously served as Chief Financial Officer of ESSA Pharma Inc. and as Head of Finance and Corporate Development, Secretary and Treasurer at Celator Pharmaceuticals Inc., now part of Jazz Pharmaceuticals. He received a B.Sc. in Biology from Queen’s University, an M.B.A. from University of Western Ontario and holds a CPA, CMA accounting designation.
Jason Crawford
EVP R&D
Jason leads drug discovery and development at 3C Therapeutics. Previously, he served as Executive Vice President of Discovery at Gandeeva, where he led efforts to develop molecular glues targeting K-Ras and other traditionally “undruggable” targets. Before Gandeeva, he held roles of increasing scientific responsibility and portfolio oversight at adMare BioInnovations (formerly CDRD), with the most senior role as Venture Partner. Prior to adMare, Jason was at AnorMED Inc. where he was a Manager of Development Chemistry and led the drug substance CMC efforts to enable pre-clinical and outsourced GMP production for mavorixafor (Xolremdi) for preclinical to Phase 2 clinical trials, and for plerixafor (Mozobil) for Phase 2 through to regulatory approval. Jason also held medicinal chemistry roles at AnorMED and Microcide Inc. Jason received his BSc and PhD from the University of Victoria and conducted postdoctoral research at Ohio State University.
What's happening
News & events
View All →Upcoming
Nov 3–4, 2026
3C Therapeutics to present at Invest in BC 2026
Presenting · Vancouver Convention Centre West
Get in touch
Contact 3C Therapeutics to discuss investment, partnering opportunities or scientific collaborations.